Recall Notices

After notification of any recall, Express Scripts will continue processing new and refill prescriptions with product from non-recalled lots or manufacturers, if available. Please visit the U.S. Food and Drug Administration (FDA) website for the most up-to-date information on drug safety and recalls.

Sodium Chloride IV Bags Recalled
June 30, 2025
On June 17, 2025, B. Braun Medical Inc. issued a recall for 0.9% (Sodium Chloride) NACL INJ USP 500mL due to potential fluid leakage from small pinholes in the IV bags.
Device Correction for Dexcom
June 30, 2025
On May 12, 2025, Dexcom issued an Urgent Medical Device Correction for Dexcom G6 and G7 receivers.
Swabflush Prefilled Syringes with SwabCaps Recalled
June 30, 2025
On June 18, 2025, Medline Industries, LP issued a recall for specific lots of SwabFlush™ Prefilled Syringes with ICU Medical SwabCaps™.
Sulfamethoxazole/Trimethoprim Recalled
June 06, 2025
On June 2, 2025, Amneal Pharmaceuticals recalled three lots of sulfamethoxazole/trimethoprim tablets, USP, 400mg/80mg to the consumer level.
Metoclopramide Recall
June 02, 2025
On May 23, 2025, Teva Pharmaceuticals USA recalled one lot of metoclopramide 10mg tablets to the consumer level.
Gamunex-C 40G Vials Withdrawn
April 08, 2025
On March 21, 2025, Grifols Therapeutics LLC withdrew one additional lot of Gamunex-C® (immune globulin injection [human]
Sodium Bicarbonate Recalled
March 26, 2025
On March 13, 2025, Exela Pharma Sciences, LLC recalled two lots of 8.4% sodium bicarbonate injection, USP 50mEq/50mL.
Gamunex-C Lot Withdrawn
March 05, 2025
On Feb. 20, 2025, Grifols Therapeutics LLC withdrew one lot Gamunex-C® (immune globulin injection [human], 10% caprylate/chromatography purified) 40G vial to the consumer level for due to an increased rate of reported hypersensitivity reactions with the affected lot.
Fentanyl Transdermal Recalled
February 21, 2025
On Jan. 31, 2025, Alvogen, Inc. issued a recall for one lot to the consumer level for Fentanyl Transdermal System 25 mcg/h transdermal patches.
Additional Lot of Xembify Withdrawn
February 11, 2025
On Jan. 10, 2025, Grifols Therapeutics LLC withdrew one lot to the consumer level for Xembify® (immune globulin subcutaneous, human-klhw) 20% 4G vial due to an increased rate of reported hypersensitivity reactions with the affected lot.

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.